[1] |
孔雨薇, 王立贵, 杜昕颖, 等. 2012—2018年北京市抗结核药物使用趋势分析. 中华医院感染学杂志, 2020, 30(8):1228-1233. doi: 10.11816/cn.ni.2020-193263.
doi: 10.11816/cn.ni.2020-193263
|
[2] |
中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019, 41(10):1025-1073. doi: 10.3969/j.issn.1000-6621.2019.10.001.
doi: 10.3969/j.issn.1000-6621.2019.10.001
|
[3] |
Li G, Zhang J, Jiang Y, et al. Cross-resistance of isoniazid, para-aminosalicylic acid and pasiniazid against isoniazid-resistant Mycobacterium tuberculosis isolated in China. J Glob Antimicrob Resist, 2020, 20:275-281. doi: 10.1016/j.jgar.2019.08.005.
doi: 10.1016/j.jgar.2019.08.005
URL
|
[4] |
刘银萍, 王杰, 张俊仙, 等. 对异烟肼与丙硫异烟胺耐药的结核分枝杆菌临床分离株检测及相关基因基因突变的研究. 中国防痨杂志, 2016, 38(9):718-721. doi: 10.3969/j.issn.1000-6621.2016.09.05.
doi: 10.3969/j.issn.1000-6621.2016.09.05
|
[5] |
周爱萍, 张敏, 李文侠, 等. 西安市耐异烟肼的结核杆菌耐药性及分子特征分析. 中国现代医学杂志, 2018, 28(12):53-57. doi: 10.3969/j.issn.1005-8982.2018.12.009.
doi: 10.3969/j.issn.1005-8982.2018.12.009
|
[6] |
Huo F, Lu J, Zong Z, et al. Change in prevalence and molecular characteristics of isoniazid-resistant tuberculosis over a 10-year period in China. BMC Infect Dis, 2019, 19(1):689. doi: 10.1186/s12879-019-4333-4.
doi: 10.1186/s12879-019-4333-4
URL
|
[7] |
Vilchèze C, Jacobs WR Jr. Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities. Microbiol Spectr, 2014, 2(4): MGM2-0014-2013. doi: 10.1128/microbiolspec.MGM2-0014-2013.
doi: 10.1128/microbiolspec.MGM2-0014-2013
|
[8] |
中华医学会结核病学分会临床检验专业委员会. 结核病病原学分子诊断专家共识. 中华结核和呼吸杂志, 2018, 41(9):688-695. doi: 10.3760/cma.j.issn.1001-0939.2018.09.008.
doi: 10.3760/cma.j.issn.1001-0939.2018.09.008
|
[9] |
Baker LV, Brown TJ, Maxwell O, et al. Molecular analysis of isoniazid-resistant Mycobacterium tuberculosis isolates from England and Wales reveals the phylogenetic significance of the ahpC-46A polymorphism. Antimicrob Agents Chemother, 2005, 49(4):1455-1464. doi: 10.1128/AAC.49.4.1455-1464.2005.
doi: 10.1128/AAC.49.4.1455-1464.2005
pmid: 15793126
|
[10] |
李亮, 唐神结, 杜建, 等. 建国70年我国结核病化学治疗的回顾与展望. 中华结核和呼吸杂志, 2019, 42(10):723-726. doi: 10.3760/cma.j.issn.1001-0939.2019.10.002.
doi: 10.3760/cma.j.issn.1001-0939.2019.10.002
|
[11] |
Zhang T, Jiang G, Wen S, et al. Para-aminosalicylic acid increases the susceptibility to isoniazid in clinical isolates of Mycobacterium tuberculosis. Infect Drug Resist, 2019, 12:825-829. doi: 10.2147/IDR.S200697.
doi: 10.2147/IDR.S200697
URL
|
[12] |
马玙, 朱莉贞, 潘毓萱. 结核病. 北京:人民卫生出版社, 2006: 12.
|
[13] |
World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019.
|
[14] |
马进宝, 任斐, 曾令城, 等. 2015—2019年西安市680例耐多药结核病患者耐药情况分析. 中国防痨杂志, 2020, 42(6):609-613. doi: 10.3969/j.issn.1000-6621.2020.06.013.
doi: 10.3969/j.issn.1000-6621.2020.06.013
|
[15] |
赵冰, 宋媛媛, 逄宇, 等. 中国耐多药结核分枝杆菌二线抗结核药物敏感性分析. 中国防痨杂志, 2013, 35(10):831-834.
|
[16] |
宋艳华, 高孟秋, 李琦. 结核分枝杆菌对乙硫异烟胺/丙硫异烟胺耐药的机制及其增敏剂研究进展. 中国防痨杂志, 2020, 42(2):173-177. doi: 10.3969/j.issn.1000-6621.2020.02.017.
doi: 10.3969/j.issn.1000-6621.2020.02.017
|
[17] |
宋艳华, 王桂荣, 霍凤敏, 等. 耐多药和广泛耐药MTB的inhA基因基因突变与对丙硫异烟胺耐药的相关性分析. 中国防痨杂志, 2018, 40(8):821-824. doi: 10.3969/j.issn.1000-6621.2018.08.009.
doi: 10.3969/j.issn.1000-6621.2018.08.009
|
[18] |
Tan Y, Su B, Zheng H, et al. Molecular Characterization of Prothionamide-Resistant Mycobacterium tuberculosis Isolates in Southern China. Front Microbiol, 2017, 8:2358. doi: 10.3389/fmicb.2017.02358.
doi: 10.3389/fmicb.2017.02358
URL
|
[19] |
Lee JH, Jo KW, Shim TS. Correlation between GenoType MTBDRplus Assay and Phenotypic Susceptibility Test for Prothionamide in Patients with Genotypic Isoniazid Resistance. Tuberc Respir Dis (Seoul), 2019, 82(2):143-150. doi: 10.4046/trd.2018.0027.
doi: 10.4046/trd.2018.0027
URL
|
[20] |
Islam MM, Tan Y, Hameed HMA, et al. Detection of novel mutations associated with independent resistance and cross-resistance to isoniazid and prothionamide in Mycobacterium tuberculosis clinical isolates. Clin Microbiol Infect, 2019, 25(8):1041.e1-1041.e7. doi: 10.1016/j.cmi.2018.12.008.
doi: 10.1016/j.cmi.2018.12.008
|